ABOUT BIOMUNEX

BIOMUNEX is a biopharmaceutical company based in Paris (FR), with an affiliate in Cambridge, Massachusetts, USA (established in 2019), with a seasoned and international leadership team and board. Biomunex is discovering and developing differentiated immunotherapeutic approaches based on data driven biology, to address the unmet medical needs in oncology. BIOMUNEX focuses on inventing disruptive biological approaches and bringing breakthrough therapies to patients based on the discovery and development of next generation proprietary BiXAb^® bi- and multi-specific antibodies.

• Our game changing proprietary BiXAb^® technology enables BIOMUNEX to discover and develop immunotherapies for several cancer types. Our BiXAb^® technology offers key properties of an ideal bispecific platform: rapid design and modularity; excellent drug like properties; high yields and cost-effective manufacturability; multi-specific capability and versatility.
• Our rapidly evolving pipeline will soon enable BIOMUNEX to be a clinical stage company. The most advanced BiXAb^® candidates, developed for immuno-oncology applications, have demonstrated superior in vitro and in vivo efficacy in solid tumors and hematological malignancies. BIOMUNEX also initiated the discovery and development of additional BiXAb^®s for disruptive approaches in immuno-oncology in collaboration with renowned academic institutions such as the Institut Curie in Paris.

• The BiXAb^® technology and pipeline has been validated by licensing deals signed with industrial partners for development of bi- and multi-specific antibodies:

In January 2019 – Out-licensing agreement with Sanofi focused on generation and optimization of bi- and multi-specific antibody therapeutics. In February 2021 – Out-licensing and co-development agreement with Onward Therapeutics for one of the proprietary bispecific antibody programs of BIOMUNEX, and investment by Onward in financing round of BIOMUNEX. These major partnerships are in line with the company’s strategy of establishing collaboration agreements with pharma partners.